The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with rheumatoid arthritis. ⋯ In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab. (Funded by Eli Lilly and Incyte; ClinicalTrials.gov number, NCT01710358 .).